Is THYROCARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of THYROCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: THYROCARE (₹963.15) is trading above our estimate of fair value (₹716.23)
Significantly Below Fair Value: THYROCARE is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for THYROCARE?
Key metric: As THYROCARE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for THYROCARE. This is calculated by dividing THYROCARE's market cap by their current
earnings.
What is THYROCARE's PE Ratio?
PE Ratio
60.8x
Earnings
₹839.60m
Market Cap
₹52.05b
THYROCARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
8.2x
Enterprise Value/EBITDA
34.1x
PEG Ratio
2.3x
Price to Earnings Ratio vs Peers
How does THYROCARE's PE Ratio compare to its peers?
Price-To-Earnings vs Industry: THYROCARE is expensive based on its Price-To-Earnings Ratio (60.8x) compared to the Indian Healthcare industry average (41.8x).
Price to Earnings Ratio vs Fair Ratio
What is THYROCARE's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
THYROCARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
60.8x
Fair PE Ratio
57.9x
Price-To-Earnings vs Fair Ratio: THYROCARE is expensive based on its Price-To-Earnings Ratio (60.8x) compared to the estimated Fair Price-To-Earnings Ratio (57.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst THYROCARE forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
₹963.15
₹1,007.50
+4.6%
3.2%
₹1,040.00
₹975.00
n/a
2
Nov ’25
₹927.70
₹1,007.50
+8.6%
3.2%
₹1,040.00
₹975.00
n/a
2
Oct ’25
₹828.10
₹800.00
-3.4%
3.1%
₹825.00
₹775.00
n/a
2
Sep ’25
₹861.80
₹800.00
-7.2%
3.1%
₹825.00
₹775.00
n/a
2
Aug ’25
₹818.00
₹800.00
-2.2%
3.1%
₹825.00
₹775.00
n/a
2
Jul ’25
₹650.75
₹740.00
+13.7%
1.4%
₹750.00
₹730.00
n/a
2
Jun ’25
₹612.20
₹740.00
+20.9%
1.4%
₹750.00
₹730.00
n/a
2
May ’25
₹644.95
₹727.50
+12.8%
0.3%
₹730.00
₹725.00
n/a
2
Apr ’25
₹607.00
₹722.50
+19.0%
0.3%
₹725.00
₹720.00
n/a
2
Mar ’25
₹681.45
₹722.50
+6.0%
0.3%
₹725.00
₹720.00
n/a
2
Feb ’25
₹616.55
₹730.00
+18.4%
1.4%
₹740.00
₹720.00
n/a
2
Jan ’25
₹652.35
₹695.00
+6.5%
6.5%
₹740.00
₹650.00
n/a
2
Dec ’24
₹566.35
₹632.50
+11.7%
2.8%
₹650.00
₹615.00
n/a
2
Nov ’24
₹546.65
₹632.50
+15.7%
2.8%
₹650.00
₹615.00
₹927.70
2
Oct ’24
₹568.30
₹647.50
+13.9%
0.4%
₹650.00
₹645.00
₹828.10
2
Sep ’24
₹537.85
₹647.50
+20.4%
0.4%
₹650.00
₹645.00
₹861.80
2
Aug ’24
₹590.40
₹737.00
+24.8%
13.2%
₹834.00
₹640.00
₹818.00
2
Jul ’24
₹517.95
₹782.00
+51.0%
6.6%
₹834.00
₹730.00
₹650.75
2
Jun ’24
₹455.95
₹782.00
+71.5%
6.6%
₹834.00
₹730.00
₹612.20
2
May ’24
₹441.80
₹782.00
+77.0%
6.6%
₹834.00
₹730.00
₹644.95
2
Apr ’24
₹429.85
₹782.00
+81.9%
6.6%
₹834.00
₹730.00
₹607.00
2
Mar ’24
₹450.75
₹782.00
+73.5%
6.6%
₹834.00
₹730.00
₹681.45
2
Feb ’24
₹531.75
₹743.33
+39.8%
9.3%
₹834.00
₹666.00
₹616.55
3
Jan ’24
₹618.65
₹743.33
+20.2%
9.3%
₹834.00
₹666.00
₹652.35
3
Dec ’23
₹631.40
₹743.33
+17.7%
9.3%
₹834.00
₹666.00
₹566.35
3
Nov ’23
₹644.20
₹785.33
+21.9%
16.1%
₹960.00
₹666.00
₹546.65
3
Analyst Forecast: Target price is less than 20% higher than the current share price.